Dr. Hu brings more than 20 years of experience in drug discovery, operational management, and business development. He previously held senior executive roles at WuXi AppTec, where he oversaw a wide variety of project collaborations with over 30 multinational corporations and biotech companies. Prior to that, he conducted small-molecule drug R&D in neurology, oncology, and inflammation at Merck and Amgen in the US.

Before founding SciBrunch Therapeutics, Dr. Hu served as co-founder and CEO of Usynova Pharmaceuticals. Under his leadership, the company successfully pivoted from protein therapeutics to innovative small-molecule drug discovery within three years. He built a highly productive research team that developed UA022—a preclinical oral inhibitor of KRAS G12D— and led its exclusive global out-licensing to AstraZeneca in 2023.

Dr. Hu earned his PhD in organic synthetic chemistry from Boston University and completed postdoctoral research under Nobel Laureate Professor E. J. Corey at Harvard University. He also holds an EMBA from China Europe International Business School (CEIBS).

Dr. Zhang is a seasoned medicinal chemist with over 20 years of experience in drug discovery. Prior to founding SciBrunch Therapeutics, he served as Vice President at WuXi AppTec's DDSU, where he successfully delivered more than 30 preclinical projects with competitive advantages to both domestic and international clients.

During his tenure at DDSU, Dr. Zhang led the research and development of over 20 small-molecule inhibitor programs in oncology, many of which have advanced to various clinical stages. Additionally, several preclinical oncology assets developed under his leadership have been successfully out-licensed internationally. Key targets include KRAS G12D (off), KRAS G12C (off), panRAS (on), and panKRAS (off).

Dr. Zhang earned an MS from Nankai University and a PhD in Organic Chemistry from Lehigh University, followed by postdoctoral research at the University of Utah. He is an inventor on more than 300 international patents and has authored over 20 peer-reviewed articles in drug discovery.

Dr. Hu brings more than 20 years of experience in drug discovery, operational management, and business development. He previously held senior executive roles at WuXi AppTec, where he oversaw a wide variety of project collaborations with over 30 multinational corporations and biotech companies. Prior to that, he conducted small-molecule drug R&D in neurology, oncology, and inflammation at Merck and Amgen in the US.

Before founding SciBrunch Therapeutics, Dr. Hu served as co-founder and CEO of Usynova Pharmaceuticals. Under his leadership, the company successfully pivoted from protein therapeutics to innovative small-molecule drug discovery within three years. He built a highly productive research team that developed UA022—a preclinical oral inhibitor of KRAS G12D— and led its exclusive global out-licensing to AstraZeneca in 2023.

Dr. Hu earned his PhD in organic synthetic chemistry from Boston University and completed postdoctoral research under Nobel Laureate Professor E. J. Corey at Harvard University. He also holds an EMBA from China Europe International Business School (CEIBS).

Dr. Zhang is a seasoned medicinal chemist with over 20 years of experience in drug discovery. Prior to founding SciBrunch Therapeutics, he served as Vice President at WuXi AppTec's DDSU, where he successfully delivered more than 30 preclinical projects with competitive advantages to both domestic and international clients.

During his tenure at DDSU, Dr. Zhang led the research and development of over 20 small-molecule inhibitor programs in oncology, many of which have advanced to various clinical stages. Additionally, several preclinical oncology assets developed under his leadership have been successfully out-licensed internationally. Key targets include KRAS G12D (off), KRAS G12C (off), panRAS (on), and panKRAS (off).

Dr. Zhang earned an MS from Nankai University and a PhD in Organic Chemistry from Lehigh University, followed by postdoctoral research at the University of Utah. He is an inventor on more than 300 international patents and has authored over 20 peer-reviewed articles in drug discovery.